title: Induction intraarterial chemotherapy for T4 breast cancer through an implantable port-catheter system.
abstract: Eleven patients with T4 breast cancer received induction intraarterial chemotherapy (IACT) as the first step in multidisciplinary therapy. The IACT agents (epirubicin and mitomycin C), were delivered weekly in the outpatient department by bolus injection through an implantable port-catheter system. A modified technique of port-catheter system implantation was used. The precise localization of the catheter was dually confirmed by angiography and dye test. The effectiveness of the treatment was evaluated by clinical appearance, image study, and microscopic examination. A 91% response rate was obtained, and the lesions were resectable in < or = 8 weeks. No obvious systemic toxicity resulted from the IACT. Our results show that weekly IACT by bolus injection through a port-catheter system for treating locally advanced T4 breast cancer is feasible and efficacious.
authors.affiliation: Department of Surgery, Veterans General Hospital-Kaohsiung, School of Medicine, National Yang-Ming University, Taiwan, R.O.C.
authors.forename: H T
authors.initials: HT
authors.lastname: Chang
authors.forename: K T
authors.initials: KT
authors.lastname: Mok
authors.forename: W S
authors.initials: WS
authors.lastname: Tzeng
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D015901:Angiography, Digital Subtraction; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D001916:Brachial Artery / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002406:Catheterization, Peripheral / Q000295:instrumentation; D002408:Catheters, Indwelling; D004396:Coloring Agents; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial / Q000295:instrumentation; D008323:Mammary Arteries / Q000000981:diagnostic imaging; D008327:Mammography; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009367:Neoplasm Staging; D012074:Remission Induction; D013348:Subclavian Artery / Q000000981:diagnostic imaging; D016896:Treatment Outcome; D016217:Ultrasonography, Mammary
chemical_list: D000903:Antibiotics, Antineoplastic; D004396:Coloring Agents; D015251:Epirubicin; D016685:Mitomycin